Cancer Research - Europa

More documents

Recommendations

Info

Keywords | Cancer incidence | prevention | risk factors | smoking | alcohol | overweight | fruit and vegetables | physical activity | EUROCADET Key determinants of the future incidence of cancer across Europe: impact of prevention Summary Up to 40 % of Europeans will suff er from cancer at some time in their life and, in middle age, 40 % of all deaths are due to this disease. Since up to 40 % of cancers may also be preventable, primary prevention remains essential, as the European Cancer Code also emphasises. Entry-points for preventive interventions were identifi ed based on known risk factors for cancer, partly overlapping with other chronic diseases. Yet, with the exception of hygienic and occupational measures and discouraging smoking, primary prevention was not very successful, especially in lower socio-economic status (SES) groups; avoidable exposure to risk factors demands more attention. This project aims to underpin national and European policies to prevent cancer by providing estimates of the potential impact of interventions on determinants of cancer incidence on the future burden of cancer in Europe. Specifi - cally, we aim to: • estimate the prevalence and quantitative impact of major lifestyle (smoking, excessive alcohol use, fruit and vegetable consumption, overweight and physical activity) and socio-economic determinants on cancer incidence, concerning cancers of the oral cavity, larynx, lung, oesophagus, stomach, pancreas, colo-rectum, bladder, kidney, breast, endometrium and prostate, comprising 60 % of the incidence; • assess the potential to reduce exposure to these determinants by reviewing evidence of eff ectiveness of interventions and policies as well as barriers to implementation; • estimate the future burden of cancer across Europe based on autonomous trends and various scenarios of implementation of eff ective interventions. This coordination action will generate intensive interaction with national and international researchers, and policy-makers who will provide input to scenario development and refl ect on its outcome so that ambitious policies can be rolled out. Regional workshops will serve to implement scenario development for prevention, based on the Prevent model developed at Erasmus MC in Rotterdam. A special web portal will be designed allowing for interactive communication among participants, archiving of relevant data and development of scenarios, and enabling Member States to adapt to their needs (‘do-it-yourself’) and circumstances, possibly also beyond the project. Problem Extensive research in the fi eld of cancer aetiology and prevention has been performed in the last decades and is still going on. However, a systematic over view and integration of (in)eff ective strategies, their prerequisites, effi cacy and possible impact is lacking. This project aims to integrate and synthesise the current knowledge of and experience with eff ective preventive activities, and project their expected eff ects on the future burden of cancer in Europe. 100 CANCER RESEARCH PROJECTS FUNDED UNDER THE SIXTH FRAMEWORK PROGRAMME Aim The aim is to underpin and promote implementation of European and national policies to prevent cancer by providing estimates of the potential impact that interventions directed at key determinants of the incidence of this disease may have on the future burden of cancer in the various parts of Europe up to 2040. Expected impact The impact of this project will be that a perspective for cancer prevention is shown, which makes maximal use of existing knowledge in such a way that policy-makers are persuaded to invest more in eff ective long-term prevention eff orts. Furthermore, the project will help in formulating realistic targets at realistic terms (often over decades) to be reached by preventive measures designed to reduce the exposure to risk factors and/or the incidence of cancer, but also make recommendations for the further studies needed to improve primary prevention eff orts to reduce the burden of cancer. Potential applications Benefi ting from preventive actions directed at chronic diseases such as cancer, diabetes and cardio-vascular disease, this coordination action for cancer prevention prepares a solid basis for fur ther active evidence–based preventive policies that can aff ect many generations of Europeans born since the 1940s, but especially since the 1980s and 90s, by combining evidence with incentives to change unhealthy habits or not star t them, which is more relevant for the younger generations. European variation can provide an irresistibly strong example of the potential eff ects that changes in lifestyle can have. In this respect, the systematic attention for the role of socio-economic status (SES) is impor tant. The approach to estimate the long-term impact of prevention by means of scenario development opens the way for involving a broad array of stakeholders who are robbed of excuses not to act. The scenarios will be made available at a special web por tal, allowing the Member States and regions to adapt the input to their specifi c needs and circumstances, and creating an oppor tunity for interaction with policy-makers at European, national and international levels.
Coordinator Jan Willem Coebergh Johan Mackenbach Dept. of Public Health Erasmus MC Rotterdam, The Netherlands j.coebergh@erasmusmc.nl j.mackenbach@erasmusmc.nl Partners J. Brug A. Kunst Dept. of Public Health Erasmus MC Rotterdam, The Netherlands j.brug@erasmusmc.nl a.kunst@erasmusmc.nl Knut-Inge Klepp University of Oslo Dept. of Nutrition Faculty of Medicine Oslo, Norway k.i.klepp@medisin.uio.no Josép Borras Institut Català d’Oncologia L’Hospitalet de Llobregat, Spain jmborras@ico.scs.es Philippe Autier Paolo Boffetta Paola Pisani International Agency for Research on Cancer – IARC Lyon, France autierp@iarc.fr boffetta@iarc.fr paola.pisani@ndm.ox.ac.uk PREVENTION Hermann Brenner Deutsches Krebsforschungszentrum Heidelberg, Germany brenner@dzfa.uni-heidelberg.de Giuseppe Costa Azienda Sanitaria Locale 5 Servizio di epidemiologia Grugliasco (Torino), Italy giuseppe.costa@epi.piemonte.it Andrea Micheli Instituto Nazionale per lo Studio e la Cura dei Tumori Milano, Italy micheli@istitutotumori.mi.it Eero Pukkala Finnish Cancer Registry Helsinki, Finland eero.pukkala@cancer.fi Hans Storm Anne Tjonneland Danish Cancer Society Copenhagen, Denmark hans@cancer.dk, annet@cancer.dk Antonia Trichopoulou University of Athens School of Medicine Dept. of Hygiene and Epidemiology Athens, Greece antonia@nut.uoa.gr Witold Zatonski The Maria-Slodowska-Curie Cancer Center and Institute of Oncology Dept. of Epidemiology and Cancer Prevention Warsaw, Poland zatonskiw@coi.waw.pl Project number SP23-CT-2005-006528 EC contribution € 987 963 Duration 48 months Starting date 01/04/2005 Instrument CA Project web-site www.eurocadet.org 101
Page 1 and 2:
PROJECT SYNOPSES CANCER RESEARCH PR
Page 3 and 4:
CANCER RESEARCH PROJECTS FUNDED UND
Page 5 and 6:
TABLE OF CONTENTS FOREWORD - CANCER
Page 7 and 8:
Prevention 97 EPIC 98 EUROCADET 100
Page 9 and 10:
CANCER: COMBATING A COMPLEX DISEASE
Page 11 and 12:
Biology Cancer is a disease ethat t
Page 13 and 14:
p53 activators ASPP Partner 5 NFkap
Page 15 and 16:
Keywords | Angiogenesis | vasculoge
Page 17 and 18:
Keywords | Tumour-host interactions
Page 19 and 20:
Keywords | Breast | metastasis | ge
Page 21 and 22:
Keywords | Identifi cation of novel
Page 23 and 24:
Keywords | Systems biology | modell
Page 25 and 26:
Keywords | Oncology | anticancer th
Page 27 and 28:
• public health research coupled
Page 29 and 30:
Expected results We will construct
Page 31 and 32:
Potential applications Our DNA is u
Page 33 and 34:
Microscopic examination of tissue s
Page 35 and 36:
Pluripotent embryonic stem cells ar
Page 37 and 38:
• Decryption of the leukaemia cel
Page 39 and 40:
• identifi cation of molecular ta
Page 41 and 42:
A B C LT-HSC CSC The Cancer Stem Ce
Page 43 and 44:
X-ray diff raction of target drug c
Page 45 and 46:
using pathway-specifi c reporter ce
Page 47 and 48:
Keywords | Kinases | pediatric panc
Page 49 and 50:
Keywords | Lymphangiogenesis | angi
Page 51 and 52: Keywords | Breast cancer | metastas
Page 53 and 54: Keywords | Mitosis | phosphorylatio
Page 55 and 56: Keywords | Therapy | genome | telom
Page 57 and 58: Keywords | Multiple myeloma | cance
Page 59 and 60: Keywords | p53 tumour suppressor |
Page 61 and 62: Development of eff ective anti-canc
Page 63 and 64: Coordinator Patrick A. Curmi INSERM
Page 65 and 66: Drosophila as a model system for tu
Page 67 and 68: Normal cell growth and epithelial l
Page 69 and 70: effi ciently with cancer cell proli
Page 71 and 72: A high-throughput assay of transcri
Page 73 and 74: Coordinator Ewa Sikora Nencki Insti
Page 75 and 76: Expected results The SIROCCO consor
Page 77 and 78: Keywords | Epigenetics | gene regul
Page 79 and 80: Keywords | Hereditary | tricarboxyl
Page 81 and 82: Keywords | HSV-1 | hepatocellular c
Page 83 and 84: Keywords | Apoptosis | autophagy |
Page 85 and 86: Keywords | Tumour | host | signalli
Page 87 and 88: Aetiology The uncontrolled cell gro
Page 89 and 90: Coordinator Rosalind Eeles Reader i
Page 91 and 92: The parallelogram approach in CARCI
Page 93 and 94: Keywords | Melanoma | genetics | na
Page 95 and 96: Keywords | Virus | bacteria | HPV |
Page 97 and 98: Keywords | Breast | prostate | gene
Page 99 and 100: Prevention The fact that preventing
Page 101: Coordinator Elio Riboli Imperial Co
Page 105: Coordinator Jose M a Benlloch Conse
Page 108 and 109: BAMOD Breath-Gas Analysis for Molec
Page 110 and 111: BioCare Molecular Imaging for Biolo
Page 112 and 113: These centres of excellence will in
Page 114 and 115: Expected results Optimise the benef
Page 116 and 117: 114 Cell proliferation and apoptosi
Page 118 and 119: COBRED Colon and Breast cancer Diag
Page 120 and 121: DASIM Diagnostic Applications of Sy
Page 122 and 123: Expected results Primarily, the res
Page 124 and 125: Coordinator John A. Foekens Dept. o
Page 126 and 127: 124 Aim Drop-Top has two major obje
Page 128 and 129: Coordinator Gorka Ochoa Progenika B
Page 130 and 131: Expected results The E.E.T.-Pipelin
Page 132 and 133: e developed by eTUMOUR is likely to
Page 134 and 135: Coordinator Angel Porgador Ben-Guri
Page 136 and 137: • the design of a compact assembl
Page 138 and 139: Potential applications We believe t
Page 140 and 141: Tumor initiation, progression to ma
Page 142 and 143: MolDiag-Paca Novel Molecular Diagno
Page 144 and 145: NEMO Nano based capsule-Endoscopy w
Page 146 and 147: OVCAD Ovarian Cancer - Diagnosis of
Page 148 and 149: P-MARK Validation of recently devel
Page 150 and 151: POC4life Multiparametric quantum do
Page 152 and 153:
PROMET Prostate cancer molecular-or
Page 154 and 155:
Micrometastasis in the bone marrow.
Page 156 and 157:
and pharmaco-kinetics studies. This
Page 158 and 159:
Coordinator Raffaella Giavazzi Isti
Page 160 and 161:
• Development of tools for diagno
Page 163 and 164:
Treatment Two major problems when t
Page 165 and 166:
Coordinator Lluis M. Mir UMR 8121 C
Page 167 and 168:
Potential applications ANGIOSTOP ha
Page 169 and 170:
Green-fl uorescence protein- expres
Page 171 and 172:
Coordinator Robert Hawkins Universi
Page 173 and 174:
Expected results The BACULOGENES pr
Page 175 and 176:
descriptors of the molecules to be
Page 177 and 178:
Keywords | Therapeutic vaccine | im
Page 179 and 180:
Keywords | Cancer chemotherapy | dr
Page 181 and 182:
Keywords | Children | cancer | leuk
Page 183 and 184:
Chimaeric TCR shown in context of n
Page 185 and 186:
Andrea Splendiani Leaf Bioscience s
Page 187 and 188:
Coordinator Anne O’Garra The Medi
Page 189 and 190:
Coordinator Jacques Bartholeyns IDM
Page 191 and 192:
Structure Driven Drug Design The in
Page 193 and 194:
• acquire fundamental knowledge a
Page 195 and 196:
Terry Jones Victoria University of
Page 197 and 198:
Potential applications The use of t
Page 199 and 200:
groups and management structures. T
Page 201 and 202:
T. Barbui Azienda Ospedaliera-Osped
Page 203 and 204:
Keywords | Mantle cell lymphoma | t
Page 205 and 206:
Keywords | Hypoxia | HIF | pericell
Page 207 and 208:
Keywords | Radiation-induced compli
Page 209 and 210:
Keywords | Gene therapy | adenoviru
Page 211 and 212:
Keywords | Dependence receptors | a
Page 213 and 214:
Keywords | Photodynamic therapy | a
Page 215 and 216:
Keywords | Ovarian cancer | thymidy
Page 217 and 218:
Keywords | Quality assurance | clin
Page 219 and 220:
Keywords | Circadian | clocks | cel
Page 221 and 222:
Keywords | Anticancer therapy | onc
Page 223 and 224:
Coordinator Monika Lusky Transgene
Page 225 and 226:
6 000 women over a three-year perio
Page 227 and 228:
Keywords | Solid tumours | apoptosi
Page 229 and 230:
Keywords | Lymphoma | leukaemia | v
Page 231:
Coordinator Riccardo Dolcetti Centr
Page 234 and 235:
CCPRB Cancer Control using Populati
Page 236 and 237:
EPCRC The European Palliative Care
Page 238 and 239:
EUROCAN+PLUS Feasibility Study for
Page 240 and 241:
EUSTIR A European strategy for the
Page 242 and 243:
NORMOLIFE Development of new therap
Page 245 and 246:
Scientifi c Model Systems The compl
Page 247 and 248:
Performance of benchmarking exercis
Page 249 and 250:
• markers correlating with the im
Page 251 and 252:
Indices - Keywords Indices - Partne
Page 253 and 254:
● disease markers 131 ● DNA dam
Page 255 and 256:
● renal 77 ● replication 219
Page 257 and 258:
Bos, Nico A. 56 Boskovic, Darinka 2
Page 259 and 260:
Geley, Stephan 159 Georgopoulos, Li
Page 261 and 262:
Lingner, Joachim 54 Linial, Michal
Page 263 and 264:
Ragno, Pia 115 Rainford, Martyn 92
Page 265 and 266:
Vernos, Isabelle 22 Veronesi, Umber
Page 267 and 268:
● Centre Hospitalier Universitair
Page 269 and 270:
● IFOM - Fondazione Istituto FIRC
Page 271 and 272:
● National University of Ireland
Page 273 and 274:
● University of Bari 174 ● Univ
Page 275 and 276:
HOW TO OBTAIN EU PUBLICATIONS Our p
show all

Cancer Research - Europa

Create successful ePaper yourself

Delete template?

Save as template?